Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
Physician Assistant Studies
John Cavenagh, MBA, PhD, PA-C
OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin A is an effective treatment for children who have lower limb spasticity from cerebral palsy.
STUDY DESIGN: The study by Carraro et al was a randomized double-blind clinical trial done in 2015.6The study done by Kim et al was a randomized, double-blind controlled clinical trial done in 2010.7 The study by Py et al was a clinical trial done in 2005-2006.8
DATA SOURCES: Data sources obtained for this review were articles published in peerreviewed journals found using PubMed Database.
OUTCOMES MEASURED: The outcome measured the effectiveness of Botox and Botox verse Xeomin and Neuronox, as well as the improvement of Gross Motor function with the use of Botox and Neuronox.
RESULTS: The study Carraro et al showed that incobotulinum toxin A (Xeomin) was just as effective for the treatment of spasticity from cerebral palsy, as onabotulinum toxin A (Botox).6The study by Kim et al, showed the Neuronox was just as effective as Botox.7Lastly, the study by Py et al, provided clear evidence that onabotulinum toxin A (Botox), was an effective treatment of spastic gait in cerebral palsy in the first place.8
CONCLUSIONS: The results of the studies showed at Xeomin, Neuronox, and Botox all have similar results efficacy for the treatment of lower limb spasticity in children with cerebral palsy.
Terrell, Lauren, "Is Botulinum toxin A an effective treatment for treating children who have lower limb spasticity from cerebral palsy?" (2018). PCOM Physician Assistant Studies Student Scholarship. 376.